CK Life Sciences FY26 H1 net loss narrows 81% to HK$28.7 million; revenue rises 4.22% to HK$2.72 billion

• CK Life Sciences posted a loss attributable to shareholders of HK$ 28.7 million, narrowing 81% from a year earlier.
• Revenue rose 4.22% to HK$ 2.72 billion, while basic loss per share improved to (0.30) cents.
• R&D spending fell to HK$ 97.9 million due to the Polynoma transaction and a change in consolidation treatment tied to RNAZ control approval.
• Pain unit Dogwood advanced Halneuron into Phase 2b with encouraging interim results; an open-label extension study is underway.
• TransCode moved TTX-MC138 into Phase 2a; Sequencio began planning IND-enabling studies for CKLS118 and CKLS202.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CK Life Sciences International (Holdings) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12298154), on August 25, 2026, and is solely responsible for the information contained therein.